Last 12 months
Inside the activity.
4 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 4 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2020 Filed Jun 12, 2020 20:16 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 1,500 | $1.78 | $2,670.00 |
DisclosureSEC source: 0001209191-20-036254 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,664,893 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.78 to $1.79, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 17:52 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 3,500 | $1.71 | $5,985.00 |
DisclosureSEC source: 0001209191-20-035475 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,663,393 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.78, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 17:52 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 2,700 | $1.69 | $4,563.00 |
DisclosureSEC source: 0001209191-20-035475 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,659,893 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.60 to $1.75, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 19:50 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 3,200 | $1.61 | $5,152.00 |
DisclosureSEC source: 0001209191-20-034946 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,657,193 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 19:50 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 2,500 | $1.59 | $3,975.00 |
DisclosureSEC source: 0001209191-20-034946 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,653,993 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.57 to $1.60, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 17:12 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 4,000 | $1.52 | $6,080.00 |
DisclosureSEC source: 0001209191-20-034376 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,651,493 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.49 to $1.59, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 17:12 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 2,000 | $1.60 | $3,200.00 |
DisclosureSEC source: 0001209191-20-034376 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,647,493 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.65, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 18:14 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 2,500 | $1.60 | $4,000.00 |
DisclosureSEC source: 0001209191-20-033404 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,645,493 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.62, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 18:14 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 3,200 | $1.51 | $4,832.00 |
DisclosureSEC source: 0001209191-20-033404 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,642,993 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.58, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 28, 2020 Filed May 29, 2020 17:54 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 2,200 | $1.37 | $3,014.00 |
DisclosureSEC source: 0001209191-20-032863 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,639,793 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.33 to $1.39, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2). F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 27, 2020 Filed May 29, 2020 17:54 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 500 | $1.35 | $675.00 |
DisclosureSEC source: 0001209191-20-032863 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,637,593 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 26, 2020 Filed May 27, 2020 17:54 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 600 | $1.37 | $822.00 |
DisclosureSEC source: 0001209191-20-032256 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,637,093 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 22, 2020 Filed May 27, 2020 17:54 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 1,000 | $1.38 | $1,380.00 |
DisclosureSEC source: 0001209191-20-032256 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,636,493 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.37 to $1.38, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 21, 2020 Filed May 22, 2020 17:30 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 1,700 | $1.37 | $2,329.00 |
DisclosureSEC source: 0001209191-20-031637 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,635,493 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.39, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 20, 2020 Filed May 22, 2020 17:30 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 4,000 | $1.40 | $5,600.00 |
DisclosureSEC source: 0001209191-20-031637 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,633,793 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.50, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 18, 2020 Filed May 20, 2020 19:52 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 500 | $1.35 | $675.00 |
DisclosureSEC source: 0001209191-20-030845 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,629,793 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 15, 2020 Filed May 18, 2020 21:21 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 500 | $1.29 | $645.00 |
DisclosureSEC source: 0001209191-20-030174 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,629,293 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.30, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 14, 2020 Filed May 18, 2020 21:21 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 1,400 | $1.29 | $1,806.00 |
DisclosureSEC source: 0001209191-20-030174 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,628,793 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.30, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 13, 2020 Filed May 14, 2020 19:24 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 2,100 | $1.26 | $2,646.00 |
DisclosureSEC source: 0001209191-20-029121 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,627,393 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.25 to $1.28, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 12, 2020 Filed May 14, 2020 19:24 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 3,200 | $1.32 | $4,224.00 |
DisclosureSEC source: 0001209191-20-029121 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625,293 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.26 to $1.35, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 08, 2020 Filed May 11, 2020 22:42 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 4,900 | $1.27 | $6,223.00 |
DisclosureSEC source: 0001209191-20-028377 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,622,093 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.21 to $1.34, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 07, 2020 Filed May 11, 2020 22:42 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 2,950 | $1.25 | $3,687.50 |
DisclosureSEC source: 0001209191-20-028377 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,617,193 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.28, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 06, 2020 Filed May 7, 2020 22:42 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 1,000 | $1.30 | $1,300.00 |
DisclosureSEC source: 0001209191-20-027783 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,614,243 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:42 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 3,000 | $1.32 | $3,960.00 |
DisclosureSEC source: 0001209191-20-027783 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,613,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.33, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 04, 2020 Filed May 5, 2020 23:10 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 3,000 | $1.28 | $3,840.00 |
DisclosureSEC source: 0001209191-20-027305 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,610,243 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.27 to $1.31, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 01, 2020 Filed May 5, 2020 23:10 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 5,000 | $1.21 | $6,050.00 |
DisclosureSEC source: 0001209191-20-027305 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,607,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.29, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 18:36 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 14,000 | $1.75 | $24,500.00 |
DisclosureSEC source: 0001209191-20-024466 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,602,243 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.88, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 18:36 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 3,300 | $1.37 | $4,521.00 |
DisclosureSEC source: 0001209191-20-024466 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,588,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.30 to $1.40, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 09, 2020 Filed Apr 10, 2020 18:05 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 6,700 | $1.28 | $8,576.00 |
DisclosureSEC source: 0001209191-20-024118 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,584,943 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.19 to $1.39, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 18:05 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 3,200 | $1.30 | $4,160.00 |
DisclosureSEC source: 0001209191-20-024118 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,578,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.38, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 00:06 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 2,100 | $1.25 | $2,625.00 |
DisclosureSEC source: 0001209191-20-023886 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,575,043 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.25, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 00:06 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 4,700 | $1.26 | $5,922.00 |
DisclosureSEC source: 0001209191-20-023886 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,572,943 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.30, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 03, 2020 Filed Apr 8, 2020 00:06 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 6,200 | $1.24 | $7,688.00 |
DisclosureSEC source: 0001209191-20-023886 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,568,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.25, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 18:43 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 8,300 | $1.23 | $10,209.00 |
DisclosureSEC source: 0001209191-20-023033 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,562,043 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.15 to $1.25, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 18:43 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 22,500 | $1.27 | $28,575.00 |
DisclosureSEC source: 0001209191-20-023033 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,553,743 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.16 to $1.33, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 18:43 UTC |
LEE WILLIS CDirector · Vice Chairman & COO
|
PurchaseCommon stock, $0.001 par value | 4,000 | $1.25 | $5,000.00 |
DisclosureSEC source: 0001209191-20-022059 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 33,000 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.34, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| March 31, 2020 Filed Apr 3, 2020 01:00 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 13,200 | $1.21 | $15,972.00 |
DisclosureSEC source: 0001209191-20-022897 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,531,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.32, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 30, 2020 Filed Mar 30, 2020 22:21 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 1,500 | $1.29 | $1,935.00 |
DisclosureSEC source: 0001209191-20-021746 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,518,043 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.34, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:43 UTC |
LEE WILLIS CDirector · Vice Chairman & COO
|
PurchaseCommon stock, $0.001 par value | 500 | $1.33 | $665.00 |
DisclosureSEC source: 0001209191-20-022059 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 29,000 Read SEC document |
| March 27, 2020 Filed Mar 30, 2020 22:21 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 3,500 | $1.21 | $4,235.00 |
DisclosureSEC source: 0001209191-20-021746 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,516,543 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.24, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 27, 2020 Filed Mar 30, 2020 18:13 UTC |
LEE WILLIS CDirector · Vice Chairman & COO
|
PurchaseCommon stock, $0.001 par value | 3,300 | $1.05 | $3,465.00 |
DisclosureSEC source: 0001209191-20-021667 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 28,500 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.99 to $1.10, inclusive. Read SEC document |
| March 26, 2020 Filed Mar 30, 2020 22:21 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 14,200 | $1.07 | $15,194.00 |
DisclosureSEC source: 0001209191-20-021746 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,513,043 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.95 to $1.20, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 26, 2020 Filed Mar 30, 2020 18:13 UTC |
LEE WILLIS CDirector · Vice Chairman & COO
|
PurchaseCommon stock, $0.001 par value | 3,500 | $1.23 | $4,305.00 |
DisclosureSEC source: 0001209191-20-021667 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 25,200 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.15 to $1.34, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 20:48 UTC |
LEE WILLIS CDirector · Vice Chairman & COO
|
PurchaseCommon stock, $0.001 par value | 500 | $1.30 | $650.00 |
DisclosureSEC source: 0001209191-20-021130 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 21,700 Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 20:48 UTC |
LEE WILLIS CDirector · Vice Chairman & COO
|
PurchaseCommon stock, $0.001 par value | 1,000 | $1.33 | $1,330.00 |
DisclosureSEC source: 0001209191-20-021130 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 21,200 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.33 to $1.34, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 23:57 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 4,900 | $1.48 | $7,252.00 |
DisclosureSEC source: 0001209191-20-020771 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,498,843 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.36 to $1.65, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 18, 2020 Filed Mar 18, 2020 23:27 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 3,000 | $1.46 | $4,380.00 |
DisclosureSEC source: 0001209191-20-020105 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,493,943 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.33 to $1.65, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 18:40 UTC |
LEE WILLIS CDirector · Vice Chairman & COO
|
PurchaseCommon stock, $0.001 par value | 3,500 | $1.56 | $5,460.00 |
DisclosureSEC source: 0001209191-20-020227 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 20,200 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.51 to $1.60, inclusive. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 23:27 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
PurchaseCommon stock, $0.001 par value | 2,700 | $1.61 | $4,347.00 |
DisclosureSEC source: 0001209191-20-020105 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,490,943 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.53 to $1.64, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 18:40 UTC |
LEE WILLIS CDirector · Vice Chairman & COO
|
PurchaseCommon stock, $0.001 par value | 3,050 | $1.63 | $4,971.50 |
DisclosureSEC source: 0001209191-20-020227 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 16,700 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.57 to $1.64, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.